Q&A: Benign Endometrial Cells in Women Over 40 Years of Age
Why do laboratories utilize the reporting category “Endometrial Cells Present in a Woman over 40 Years of Age”?
The Bethesda System for Reporting Cervical Cytology, in its 2001 workshop, retained the category of “Exfoliated Endometrial Cells in a Woman Greater Than 40 Years of Age”. The authors of Bethesda 2001, however do not recommend reporting this as an “epithelial abnormality,” a departure from the statement in the 1991 edition of the book.
Why was the cut-off age determined to be 40 years since not all women over 40 are post-menopausal?
The Bethesda 2001 recommendation to report the presence of benign endometrial cells in a Pap test in all patients over the age of 40 years is based on two factors: 1) the literature evidence of lack of significant endometrial pathology in patients LESS than 40 years old and 2) the lack of reliability of clinical information regarding menopausal status and clinical symptoms available to the pathologist at the time of Pap interpretation. It was decided that reporting of benign endometrial cells in a Pap test from all patients over the age of 40 would ensure uniformity of reporting. Additional specific educational comments accompanying the reporting of the endometrial cells may impact the follow up and frequency of endometrial sampling.
What comment does InCyte utilize when reporting benign endometrial cells in Pap from women over the age of 40?
“Reporting of the presence of endometrial cells in a pap test in a patient over the age of 40 is required by The Bethesda System for Reporting of Cervical Cytology specimens. The significance of this finding however is controversial. The detection of significant pathology in asymptomatic patients in follow-up of this Pap finding is very low. Please correlate clinically.”
How is it determined whether endometrial cells are “in-cycle” or “out-of-cycle”?
Correlation of the Pap finding is based upon the patient’s last menstrual period (LMP). In premenopausal women, exfoliated endometrial cells during the patient’s proliferative phase of her menstrual cycle or during the menstrual phase are commonly seen, and are interpreted as “in-cycle” normal findings. Such cells are the consequence of normal increased shedding of the endometrial lining during these phases. If the cells are present beyond two weeks from the LMP, they are interpreted as “out-of-cycle.”
In follow-up biopsies of women over 40 with benign endometrial cells on Pap, what are the most common biopsy findings?
Most follow-up biopsies in this setting are benign, and the most common cause of the presence of exfoliated benign endometrial cells in a Papanicolaou collection from a woman over 40 years of age is hormone replacement therapy (HRT). For women who are not on HRT, the most common pathologic condition encountered in follow-up biopsy is endometrial polyp, followed by leiomyoma and atrophy. In a small number of women, endometrial hyperplasia and carcinoma are identified, conditions often associated with abnormal bleeding.
Recent studies suggest that most women with endometrial carcinoma present with abnormal uterine bleeding but some studies have reported the presence of endometrial cells as the only abnormal finding (i.e. the patient is asymptomatic) in a small proportion of asymptomatic women in whom endometrial adenocarcinoma was subsequently detected.
An individual woman’s risk factors for endometrial carcinoma is determined by clinical symptoms, hormone therapy, and menopausal status.
What are the guidelines in other developed countries regarding this finding?
In the United Kingdom, the NorthEast, Yorkshire and Humber cervical cytology services recently reviewed their guidelines for reporting endometrial cells on a Pap test and adopted the following algorithm:
Laboratories are NOT required to report on the presence of benign endometrial cells in any women under the age of 50 years irrespective of the presence of known risk factors such as diabetes, tamoxifen use and polycystic ovarian syndrome. Laboratories will always report the presence of benign endometrial cells in patients who are over the age of 50 as follows:
“Negative. Endometrial cells present. Gynecologic referral should be considered if there are any clinical symptoms to suggest endometrial pathology”
In the Netherlands, where endometrial carcinoma is the leading gynecologic malignancy, reporting of benign endometrial cells in patients over the age of 40 is recommended. The Pap classification, however, was downgraded from a Pap3a (alert) to Pap1. This approach is similar to that adopted by Bethesda 2001.
In Australia, the current guidelines formulated after review of the literature concluded that there was not enough evidence to recommend reporting of benign endometrial cells in asymptomatic women of any age group and that the presence of clinical symptoms was critical in deciding referral for further evaluation of the endometrium regardless of the Pap status.
What is the best practice for follow up in women over 40 who are found to have endometrial cells on routine Pap?
The follow up algorithm should consider if the patient is symptomatic (abnormal vaginal bleeding) or asymptomatic and the patient’s menstrual status. In asymptomatic women, the incidence of endometrial abnormality is very low and literature evidence supports conservative follow up.
In our outpatient experience over the past forty years, we have found that the presence of endometrial hyperplasia or carcinoma in follow-up biopsies in women with benign endometrial cells on Pap is very low (approximately 1%).
It is important to emphasize that all symptomatic women and women with ATYPICAL endometrial cells on Pap should undergo endometrial sampling to exclude the possibility of endometrial hyperplasia or carcinoma.References:
1 Cherkis, R.C., Patten, S.F., Andrews, T.J., et al: Significance of Normal Endometrial Cells Detected by Cervical Cytology. Obstet Gynecol 71: 242, 1988.
2 Gondos B., King, B.B., Significance of Endometrial Cells in Cervicovaginal Smears. AnnClinLabSci 7: 486, 1977.
3 Ng A.B., Regan, J.W., Hawliczec S., et al: Significance of Endometrial Cells in the Detection of Endometrial Carcinoma and its Precursors. ActaCytol 18: 356, 1974.
4 Mount S.L., Wegner E.K., Eltabbakh G.H., Olmstead J.I., et al: Signficant Increase of Benign Endometrial Cells on Papanicolaou Smears in Women Using Hormone hormone replacement therapy. Obstet Gynecol 100: 445-50, 2002.
5 Brogi E., Tambouret R., Bell D.A., Classification of Benign Endometrial Glandular Cells in Cervical Smears from Postmenopausal Women. Cancer 96: 60-6, 2002.
6 Karim B.O., Burroughs F.H., Rosenthal D.L., Ali S.Z., Endometrial-type Cells in Cervico-vaginal Smears: Clinical Signficance and Cytopathologic Correlates. Diagn Cytopathol 26: 123-7, 2002.
7 Greenspan, DL, Cardillo M, Davey DD, Heller DS, et al. Endometrial cells in cervical cytology: Review of cytologic features and clinical assessment. Journal of lower gential tract disease, 10(2): 111-122, 2006.